UCB Sa operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares UCB Sa with three other
pharmaceutical manufacturers in Europe:
Protek PAO
of RUSSIAN FEDERATION
(2019
sales of 265.65 billion Russian Rubles [US$3.70 billion]
of which 70%
was Distribution),
Grifols SA
of SPAIN
(5.10 billion Euros [US$5.77 billion]
of which 78%
was Bioscience), and
Lonza Group AG
which is
based in SWITZERLAND
(5.92 billion Swiss Francs [US$6.28 billion]
of which 70%
was Pharma&Biotech).
Sales Analysis.
UCB Sa reported sales of 4.91 billion Euro (US$5.56 billion)
for the
year ending
December of 2019.
This
represents
an
increase of 6.1%
versus 2018, when the company's sales were 4.63 billion Euro.
Sales at UCB Sa have increased during each of the previous five years
(and since 2014, sales have increased a total of 47%).
Sales of Briviact saw an increase
that was more than double the company's growth rate: sales were up
55.6% in 2019, from
142.00 million Euro to 221.00 million Euro.
UCB Sa also saw significant increases in sales in
Cimzia (up 18.4% to 1.71 billion Euro)
and
Vimpat (up 20.3% to 1.32 billion Euro)
and
Other Products (up 36.2% to 440.00 million Euro)
.
Not all segments of UCB Sa experienced an increase in sales in 2019:
sales of Keppra fell 2.5% to 770.00 million Euro.
UCB Sa also experienced decreases in sales in
Neupro (down 0.6% to 319.00 million Euro)
.